What we long term investors are seeing is a question of semantics, specifically that generics are “breadcrumbs”. The point is that the NDA filings and approvals will be the most significant aspect of what the company produces. Perhaps Nasrat would have been better served by referring to the generics as appetizers to the ART/ADT entrée. Or, generics as the opening band to the ART/ADT headliner. In any event, the point is – a small generic producer is not why we are invested; we invested for the future approval of their ART/ADT products and those with patience and insight will be rewarded – handsomely.
News 
Market Data 
Discover 
AI
